Cargando…

Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study

OBJECTIVES: We aimed to assess the level of prior SARS-CoV-2 infection in socially deprived neighbourhoods after the first wave of the pandemic, and to identify factors associated with seropositivity. DESIGN: A cross-sectional study. SETTING: Three socially deprived neighbourhoods of the city of Per...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaumont, Adeline, Durand, Cécile, Ledrans, Martine, Schwoebel, Valérie, Noel, Harold, Le Strat, Yann, Diulius, Donatien, Colombain, Léa, Médus, Marie, Gueudet, Philippe, Mouly, Damien, Aumaître, Hugues
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611237/
https://www.ncbi.nlm.nih.gov/pubmed/34815286
http://dx.doi.org/10.1136/bmjopen-2021-053201
_version_ 1784603261624385536
author Beaumont, Adeline
Durand, Cécile
Ledrans, Martine
Schwoebel, Valérie
Noel, Harold
Le Strat, Yann
Diulius, Donatien
Colombain, Léa
Médus, Marie
Gueudet, Philippe
Mouly, Damien
Aumaître, Hugues
author_facet Beaumont, Adeline
Durand, Cécile
Ledrans, Martine
Schwoebel, Valérie
Noel, Harold
Le Strat, Yann
Diulius, Donatien
Colombain, Léa
Médus, Marie
Gueudet, Philippe
Mouly, Damien
Aumaître, Hugues
author_sort Beaumont, Adeline
collection PubMed
description OBJECTIVES: We aimed to assess the level of prior SARS-CoV-2 infection in socially deprived neighbourhoods after the first wave of the pandemic, and to identify factors associated with seropositivity. DESIGN: A cross-sectional study. SETTING: Three socially deprived neighbourhoods of the city of Perpignan, in the south of France, where large settled Roma communities live. PARTICIPANTS: People aged 6 years old or over, living in the study area. 700 people were included in the study using two-stage stratified sampling design. INTERVENTIONS: The study included a questionnaire and SARS-CoV-2 antibody testing by the Roche Elecsys immunoassay between 29 June and 17 July 2020. PRIMARY AND SECONDARY OUTCOME MEASURES: SARS-CoV-2 antibody seroprevalence was estimated from weighted data. Associated factors and reported symptoms were investigated using univariable and multivariable logistic regressions. RESULTS: The seroprevalence of anti-SARS-CoV-2 antibodies was 35.4% (95% CI 30.2% to 41.0%). People aged 15–64 years old had increased odds of being seropositive than those aged 65 years or over. Obese people had higher odds of being seropositive (adjusted OR (aOR)=2.0, 95% CI 1.1 to 3.8). The odds of being seropositive were higher in households with clinical COVID-19 cases (one case: aOR=2.5, 95% CI 1.3 to 5.0; several cases: aOR=6.9, 95% CI 3.1 to 15.2). In the neighbourhood with the highest measured seroprevalence, people living in a dwelling with one to two rooms had higher odds of being seropositive than those living in a four-room house (aOR=2.8, 95% CI 1.2 to 6.3). Working during the lockdown was associated with lower odds of being seropositive (aOR=0.2, 95% CI 0.03 to 1.0). CONCLUSION: Transmission of SARS-COV-2 in this vulnerable population was very high during the COVID-19 pandemic’s first wave. Our results highlight the need to strengthen and adapt preventive measures taking into account all social determinants of health, especially housing conditions.
format Online
Article
Text
id pubmed-8611237
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-86112372021-11-24 Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study Beaumont, Adeline Durand, Cécile Ledrans, Martine Schwoebel, Valérie Noel, Harold Le Strat, Yann Diulius, Donatien Colombain, Léa Médus, Marie Gueudet, Philippe Mouly, Damien Aumaître, Hugues BMJ Open Epidemiology OBJECTIVES: We aimed to assess the level of prior SARS-CoV-2 infection in socially deprived neighbourhoods after the first wave of the pandemic, and to identify factors associated with seropositivity. DESIGN: A cross-sectional study. SETTING: Three socially deprived neighbourhoods of the city of Perpignan, in the south of France, where large settled Roma communities live. PARTICIPANTS: People aged 6 years old or over, living in the study area. 700 people were included in the study using two-stage stratified sampling design. INTERVENTIONS: The study included a questionnaire and SARS-CoV-2 antibody testing by the Roche Elecsys immunoassay between 29 June and 17 July 2020. PRIMARY AND SECONDARY OUTCOME MEASURES: SARS-CoV-2 antibody seroprevalence was estimated from weighted data. Associated factors and reported symptoms were investigated using univariable and multivariable logistic regressions. RESULTS: The seroprevalence of anti-SARS-CoV-2 antibodies was 35.4% (95% CI 30.2% to 41.0%). People aged 15–64 years old had increased odds of being seropositive than those aged 65 years or over. Obese people had higher odds of being seropositive (adjusted OR (aOR)=2.0, 95% CI 1.1 to 3.8). The odds of being seropositive were higher in households with clinical COVID-19 cases (one case: aOR=2.5, 95% CI 1.3 to 5.0; several cases: aOR=6.9, 95% CI 3.1 to 15.2). In the neighbourhood with the highest measured seroprevalence, people living in a dwelling with one to two rooms had higher odds of being seropositive than those living in a four-room house (aOR=2.8, 95% CI 1.2 to 6.3). Working during the lockdown was associated with lower odds of being seropositive (aOR=0.2, 95% CI 0.03 to 1.0). CONCLUSION: Transmission of SARS-COV-2 in this vulnerable population was very high during the COVID-19 pandemic’s first wave. Our results highlight the need to strengthen and adapt preventive measures taking into account all social determinants of health, especially housing conditions. BMJ Publishing Group 2021-11-23 /pmc/articles/PMC8611237/ /pubmed/34815286 http://dx.doi.org/10.1136/bmjopen-2021-053201 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Epidemiology
Beaumont, Adeline
Durand, Cécile
Ledrans, Martine
Schwoebel, Valérie
Noel, Harold
Le Strat, Yann
Diulius, Donatien
Colombain, Léa
Médus, Marie
Gueudet, Philippe
Mouly, Damien
Aumaître, Hugues
Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title_full Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title_fullStr Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title_full_unstemmed Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title_short Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study
title_sort seroprevalence of anti-sars-cov-2 antibodies after the first wave of the covid-19 pandemic in a vulnerable population in france: a cross-sectional study
topic Epidemiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611237/
https://www.ncbi.nlm.nih.gov/pubmed/34815286
http://dx.doi.org/10.1136/bmjopen-2021-053201
work_keys_str_mv AT beaumontadeline seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT durandcecile seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT ledransmartine seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT schwoebelvalerie seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT noelharold seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT lestratyann seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT diuliusdonatien seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT colombainlea seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT medusmarie seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT gueudetphilippe seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT moulydamien seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy
AT aumaitrehugues seroprevalenceofantisarscov2antibodiesafterthefirstwaveofthecovid19pandemicinavulnerablepopulationinfranceacrosssectionalstudy